<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916822</url>
  </required_header>
  <id_info>
    <org_study_id>00033434</org_study_id>
    <nct_id>NCT03916822</nct_id>
  </id_info>
  <brief_title>Cell-based Assays for Antibody-mediated Transplant Rejection</brief_title>
  <official_title>Validating Cell-based Assays for ABMR After Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erie County Medical Center, Buffalo, NY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring, King of Prussia, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Plexision</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal: The goal of this study is to validate blood tests, which can detect antibody-mediated
      rejection (ABMR) after renal transplantation. These cell based assays measure
      CD154-expressing alloantigen-specific B-cells and their subsets in peripheral blood of adult
      renal transplant recipients. Thirty recipients will be enrolled at two transplant centers, 10
      each with ABMR, T-cell mediated rejection (TCMR), and no rejection. Each subject will be
      sample twice, before and after rejection. Donor-specific anti-HLA antibodies will also be
      measured with single antigen beads.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This cross-sectional open label study will evaluate whether alloantigen-specific B-cells and
      their subsets which express CD154 are associated with antibody-mediated rejection after first
      time renal transplantation in adult recipients.

      Control groups include adult renal transplant recipients with T-cell-mediated rejection, and
      without rejection of any type.

      Alloantigen-specific B-cells will be measured after stimulation of recipient peripheral blood
      leukocytes with those from corresponding donor and HLA-non-identical reference cells.

      Thirty total subjects will be enrolled after IRB-approved informed consent, 15 at each of two
      sites. These subjects will include ten each with biopsy-proven ABMR and TCMR and ten with no
      rejection.

      Each subject will be sampled twice, before and after treatment rejection, at intervals no
      less than 30 days, and not to exceed 90 days.

      B-cells subsets will include those that also express cytokines, and those that are
      categorized as memory or naive, and their isotope switched or unswitched subsets, transtional
      B-cells or plasmablasts, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody-mediated rejection</measure>
    <time_frame>up to 90 days per subject</time_frame>
    <description>Biopsy-proven antibody-mediated rejection after primary renal transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell mediated rejection (TCMR)</measure>
    <time_frame>up to 90 days per subject</time_frame>
    <description>Biopsy-proven TCMR after primary renal transplantation</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Antibody-Mediated Graft Rejection</condition>
  <arm_group>
    <arm_group_label>ABMR</arm_group_label>
    <description>Biopsy-proven ABMR-Banff criteria, with or without Complement binding donor-specific anti-HLA antibodies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCMR</arm_group_label>
    <description>Biopsy-proven TCMR-Banff 1A, 1B, 2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Rejection</arm_group_label>
    <description>Biopsy-proven, or clinical criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Alloantigen-specific B-cells</intervention_name>
    <description>Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry</description>
    <arm_group_label>ABMR</arm_group_label>
    <arm_group_label>No Rejection</arm_group_label>
    <arm_group_label>TCMR</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood leukocytes extracted from whole blood samples will be retained in liquid
      nitrogen for repeat testing or quality assessment until study results are public
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults who have received primary renal transplants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IRB-approved informed consent.

          -  Adults (&gt;18 yr to 70 years)

          -  Primary renal transplant recipients with biopsy-proven ABMR, TCMR or recipients with
             no rejection

        Exclusion Criteria:

          -  Lack of informed consent

          -  Concomitant BK virus infection

          -  Vulnerable populations including children &lt;18 yr, pregnant women, and prisoners
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rakesh Sindhi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Plexision</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rakesh Sindhi, MD</last_name>
    <phone>412-224-2507</phone>
    <email>rakesh@plexision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashok Reddy</last_name>
    <phone>301-651-3367</phone>
    <email>ashok.reddy@plexision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erie County Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liise Kayler, MD</last_name>
      <phone>716-361-8500</phone>
      <email>LKayler@ecmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rohan Vinayak</last_name>
      <email>rohanv@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody mediated Rejection</keyword>
  <keyword>Renal Transplantation</keyword>
  <keyword>Adults</keyword>
  <keyword>CD154</keyword>
  <keyword>B-cells</keyword>
  <keyword>B-cell subsets</keyword>
  <keyword>alloantigen-specific</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be retained at enrollment sites, Results of testing samples, and related de-identified data of the subject will be summarized and shared with all investigators of this study, and reported in publications</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

